BDBM296211 US10112942, Example 18::US10137124, Example 18::US10172851, Example 18::US10555944, Example 18::US10953005, Example 18
SMILES N#Cc1cnn2cc(OCC3COC3)cc(-c3ccc(nc3)N3CCN(Cc4ccccc4)CC3)c12
InChI Key InChIKey=CKONOADWRUZQJQ-UHFFFAOYSA-N
Data 10 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 10 hits for monomerid = 296211
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 11.7nMpH: 7.4Assay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE¿-TK assay tec...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 11.7nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE¿-TK assay tec...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 116nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE¿-TK assay tec...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 116nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE™-TK assa...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 116nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly
US Patent
Eli Lilly
US Patent
Affinity DataIC50: 11.7nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 116nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 11.7nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE™-TK assa...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly
US Patent
Eli Lilly
US Patent
Affinity DataIC50: 11.7nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair